Ovidrel Important Safety Information

Ovidrel® PreFilled Syringe is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS) and ovarian enlargement with or without pulmonary and vascular complications.

Adverse reactions reported include injection site reactions, GI disorders, abdominal pain, nausea, vomiting, ovarian cyst, ovarian hyperstimulation, and thromboembolic events. Multiple births and congenital abnormalities have been reported.

For complete information, please see full Prescribing information.

MEDICAL RESOURCES

Ovidrel® PreFilled Syringe (choriogonadotropin alfa injection)

Ovidrel® PreFilled Syringe (choriogonadotropin alfa injection) is indicated for the induction of final follicular maturation and early luteinization in infertile women who have undergone pituitary desensitization and who have been appropriately pretreated with follicle stimulating hormones as part of an Assisted Reproductive Technology (ART) program such as in vitro fertilization and embryo transfer. Ovidrel® PreFilled Syringe is also indicated for the induction of ovulation (OI) and pregnancy in anovulatory infertile patients in whom the cause of infertility is functional and not due to primary ovarian failure.

Other Resources

Ovidrel® is a registered trademark of Merck KGaA, Darmstadt, Germany or its affiliates.

Action SVG
Action SVG
Action SVG
eMedI Chat
Close
After your vist, Please answer a few questions to help us improve?
Survey
Please click on icon to provide survey...